LEXINGTON, Mass., Aug. 3, 2017 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a clinical-stage biotechnologycompany devoted to treating inflammation, inborn errors of metabolism, and other diseases related to aldehydes, today announced that Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, will present at the 37th Annual
Event: 37th Annual Canaccord Genuity Growth Conference Date: Thursday, August 10, 2017Time: 1:00 PM ETLocation: The InterContinental Hotel, Boston, MA
A live webcast of the conference call will also be available on the investor relations page of the Aldeyra Therapeutics corporate website at www.aldeyra.com. After the live webcast, the event will remain archived on the Aldeyra Therapeutics website.
About Aldeyra TherapeuticsAldeyra Therapeutics, Inc. is a biotechnology company devoted to improving lives by inventing, developing and commercializing products that treat diseases thought to be related to endogenous aldehydes, a naturally occurring class of pro-inflammatory and toxic molecules. Aldeyra's lead product candidate, ADX-102, is an aldehyde trap in development for ocular inflammation, as well as for Sjögren-Larsson Syndrome and Succinic Semi-Aldehyde Dehydrogenase Deficiency, two inborn errors of aldehyde metabolism. Aldeyra's product candidates have not been approved for sale in the U.S. or elsewhere.
Corporate Contact:Stephen TulipanoAldeyra Therapeutics, Inc.Tel: +1 781-761-4904 ext. 205 email@example.com
Investor Contact:Chris BrinzeyWestwicke PartnersTel: 339-970-2843Chris.firstname.lastname@example.org
Media Contact:Cammy Duong MacDougall Biomedical Communications email@example.com
View original content:http://www.prnewswire.com/news-releases/aldeyra-therapeutics-to-present-at-the-37th-annual-canaccord-genuity-growth-conference-300498958.html
SOURCE Aldeyra Therapeutics, Inc.
Subscribe to our Free Newsletters!
Fallopian tube cancer is a form of gynecologic cancer arising in the fallopian tubes, which are ...
Cushing syndrome is a collection of symptoms caused due to excessive amount of cortisol in the body ...
CAR T-cell therapy is a type of gene therapy where the patient's T-lymphocytes are genetically ...View All